RxDoctor Payments DataLook up a doctor →

Miguel Busquets, MD

Retina Specialist · Lexington, KYNPI 1427054808

Payments from drug & device makers

$274,275in general payments, 2019–2025

Across 495 payments — averaging $554.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$100K
  • Genentech, Inc.$83K
  • Alcon$44K
  • Carl Zeiss Meditec USA, Inc.$14K
  • Alcon Research LLC$10K
  • Notal Vision, Inc.$9K
  • plus $14K from 15 others

What the payments were for

  • Consulting fees$53,62258%
  • Speaking & faculty fees$23,91926%
  • Travel & lodging$6,9118%
  • Food & beverage$7,4468%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$274,275 in reported general payments places this provider in the 95th percentile of 22 retina specialist providers in Kentucky.

See all retina specialist providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,909,874
Medicare patients
651
Services billed
19,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate136$5,840
Alphagan PBrimonidine Tartrate22$4,990
Brimonidine Tartrate223$3,988
Difluprednate53$3,934
Bromfenac Sodium22$2,665
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$2,549
Ketorolac Tromethamine103$2,107
ErythromycinErythromycin Base122$1,257
Dorzolamide Hcl63$1,040
Acetazolamide ErAcetazolamide14$906
MoxifloxacinMoxifloxacin Hcl15$551
Timolol Maleate17$505
Latanoprost55$368
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha30$311
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat21$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P$1,332$4,99022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 retina specialist providers in Kentucky.

Other retina specialist in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →